18
Participants
Start Date
July 12, 2019
Primary Completion Date
May 31, 2024
Study Completion Date
May 31, 2025
ASTX727
ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
RECRUITING
Massachusetts General Hospital Cancer Center, Boston
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
Collaborators (1)
Astex Pharmaceuticals, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER